{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:51Z","timestamp":1792619931222,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01992-4","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T13:02:37Z","timestamp":1639227757000},"page":"221-243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Current Understanding of Narcolepsy\u00a01 and its Comorbidities: What Clinicians Need to Know"],"prefix":"10.1007","volume":"39","author":[{"given":"Lois E.","family":"Krahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis C.","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"1992_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ncl.2012.08.002","volume":"30","author":"SF Harris","year":"2012","unstructured":"Harris SF, Monderer RS, Thorpy M. Hypersomnias of central origin. Neurol Clin. 2012;30:1027\u201344.","journal-title":"Neurol Clin"},{"key":"1992_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","volume":"146","author":"MJ Sateia","year":"2014","unstructured":"Sateia MJ. International classification of sleep disorders\u2013third edition: highlights and modifications. Chest. 2014;146:1387\u201394.","journal-title":"Chest"},{"key":"1992_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9\u201318.","journal-title":"Sleep Med"},{"key":"1992_CR4","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362.","journal-title":"N Engl J Med"},{"key":"1992_CR5","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.","journal-title":"Nat Rev Dis Primers"},{"key":"1992_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.sleep.2014.01.015","volume":"15","author":"MJ Thorpy","year":"2014","unstructured":"Thorpy MJ, Krieger AC. Delayed diagnosis of narcolepsy: characterization and impact. Sleep Med. 2014;15:502\u20137.","journal-title":"Sleep Med"},{"key":"1992_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4088\/JCP.15m10262","volume":"78","author":"CM Ruoff","year":"2017","unstructured":"Ruoff CM, Reaven NL, Funk SE, et al. High rates of psychiatric comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study of 9,312 patients in the United States. J Clin Psychiatry. 2017;78:171\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1992_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5664\/jcsm.6494","volume":"13","author":"K Maski","year":"2017","unstructured":"Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13:419\u201325.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2018.06.008","volume":"85","author":"G Plazzi","year":"2018","unstructured":"Plazzi G, Clawges HM, Owens JA. Clinical characteristics and burden of illness in pediatric patients with narcolepsy. Pediatr Neurol. 2018;85:21\u201332.","journal-title":"Pediatr Neurol"},{"key":"1992_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.sleep.2014.02.001","volume":"15","author":"J Black","year":"2014","unstructured":"Black J, Reaven NL, Funk SE, et al. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014;15:522\u20139.","journal-title":"Sleep Med"},{"key":"1992_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5664\/jcsm.5594","volume":"12","author":"NM Flores","year":"2016","unstructured":"Flores NM, Villa KF, Black J, Chervin RD, Witt EA. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12:401\u20137.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR12","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Sleep-wake disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington, DC: American Psychiatric Association; 2013. p. 361\u2013422.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1992_CR13","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/03007995.2016.1208643","volume":"32","author":"C Ruoff","year":"2016","unstructured":"Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin. 2016;32:1611\u201322.","journal-title":"Curr Med Res Opin"},{"key":"1992_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.5665\/sleep.3756","volume":"37","author":"CR Baumann","year":"2014","unstructured":"Baumann CR, Mignot E, Lammers GJ, et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep. 2014;37:1035\u201342.","journal-title":"Sleep"},{"key":"1992_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.smrv.2016.08.005","volume":"35","author":"LM Trotti","year":"2017","unstructured":"Trotti LM. Waking up is the hardest thing I do all day: sleep inertia and sleep drunkenness. Sleep Med Rev. 2017;35:76\u201384.","journal-title":"Sleep Med Rev"},{"key":"1992_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5664\/jcsm.27715","volume":"6","author":"K Bagai","year":"2010","unstructured":"Bagai K, Malow BA. A novel approach to treating morning sleep inertia in narcolepsy. J Clin Sleep Med. 2010;6:77\u20138.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9:955\u201365.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR18","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1038\/s41467-020-19862-y","volume":"11","author":"A Seifinejad","year":"2020","unstructured":"Seifinejad A, Li S, Possovre ML, Vassalli A, Tafti M. Hypocretinergic interactions with the serotonergic system regulate REM sleep and cataplexy. Nat Commun. 2020;11:6034.","journal-title":"Nat Commun"},{"key":"1992_CR19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/brain\/awx096","volume":"140","author":"E Antelmi","year":"2017","unstructured":"Antelmi E, Pizza F, Vandi S, et al. The spectrum of REM sleep-related episodes in children with type\u00a01 narcolepsy. Brain. 2017;140:1669\u201379.","journal-title":"Brain"},{"key":"1992_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-319-23739-8_5","volume-title":"Narcolepsy: a clinical guide","author":"MJ Thorpy","year":"2016","unstructured":"Thorpy MJ. Diagnostic criteria and delay in diagnosis of narcolepsy. In: Goswami M, Thorpy MJ, Pandi-Perumal SR, editors. Narcolepsy: a clinical guide. 2nd ed. Cham: Springer; 2016. p. 45\u20139.","edition":"2"},{"key":"1992_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccm.2010.02.014","volume":"31","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31:371\u201381.","journal-title":"Clin Chest Med"},{"key":"1992_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.004","volume":"33","author":"J Black","year":"2017","unstructured":"Black J, Reaven NL, Funk SE, et al. Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study. Sleep Med. 2017;33:13\u20138.","journal-title":"Sleep Med"},{"key":"1992_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"WT Longstreth Jr","year":"2007","unstructured":"Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30:13\u201326.","journal-title":"Sleep"},{"key":"1992_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","volume":"20","author":"CE Mahoney","year":"2019","unstructured":"Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83\u201393.","journal-title":"Nat Rev Neurosci"},{"key":"1992_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1474-4422(14)70218-2","volume":"14","author":"RS Liblau","year":"2015","unstructured":"Liblau RS, Vassalli A, Seifinejad A, Tafti M. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14:318\u201328.","journal-title":"Lancet Neurol"},{"key":"1992_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5665\/sleep.5446","volume":"39","author":"AF Branch","year":"2016","unstructured":"Branch AF, Navidi W, Tabuchi S, et al. Progressive loss of the orexin neurons reveals dual effects on wakefulness. Sleep. 2016;39:369\u201377.","journal-title":"Sleep"},{"key":"1992_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neures.2017.03.015","volume":"118","author":"M Mieda","year":"2017","unstructured":"Mieda M. The roles of orexins in sleep\/wake regulation. Neurosci Res. 2017;118:56\u201365.","journal-title":"Neurosci Res"},{"key":"1992_CR28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41467-019-08774-1","volume":"10","author":"NW Pedersen","year":"2019","unstructured":"Pedersen NW, Holm A, Kristensen NP, et al. CD8(+) T\u00a0cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019;10:837.","journal-title":"Nat Commun"},{"key":"1992_CR29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.5664\/jcsm.8572","volume":"16","author":"D Wasserman","year":"2020","unstructured":"Wasserman D, Bassetti CLA, Rosenzweig I. Narcolepsy with resolution of cataplexy and persisting orexin deficiency. J Clin Sleep Med. 2020;16:1383\u20136.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10286-017-0473-z","volume":"28","author":"C Berteotti","year":"2018","unstructured":"Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clin Auton Res. 2018;28:545\u201355.","journal-title":"Clin Auton Res"},{"key":"1992_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-23739-8_1","volume-title":"Narcolepsy: a clinical guide","author":"S Taheri","year":"2016","unstructured":"Taheri S. The genetics of narcolepsy. In: Goswami M, Thorpy MJ, Pandi-Perumal SR, editors. Narcolepsy: a clinical guide. 2nd ed. Springer: Cham; 2016. p. 3\u201310.","edition":"2"},{"key":"1992_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5665\/sleep.3300","volume":"37","author":"M Tafti","year":"2014","unstructured":"Tafti M, Hor H, Dauvilliers Y, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2014;37:19\u201325.","journal-title":"Sleep"},{"key":"1992_CR33","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ng.372","volume":"41","author":"J Hallmayer","year":"2009","unstructured":"Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet. 2009;41:708\u201311.","journal-title":"Nat Genet"},{"key":"1992_CR34","doi-asserted-by":"publisher","unstructured":"De la Herr\u00e1n-Arita AK, Garc\u00eda-Garc\u00eda F. Narcolepsy as an immune-mediated disease. Sleep Disord. 2014;2014:792687. https:\/\/doi.org\/10.1155\/2014\/792687.","DOI":"10.1155\/2014\/792687"},{"key":"1992_CR35","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.conb.2013.04.013","volume":"23","author":"J Mahlios","year":"2013","unstructured":"Mahlios J, De la Herr\u00e1n-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013;23:767\u201373.","journal-title":"Curr Opin Neurobiol"},{"key":"1992_CR36","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1084\/jem.20160897","volume":"213","author":"FJ Hartmann","year":"2016","unstructured":"Hartmann FJ, Bernard-Valnet R, Queriault C, et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J Exp Med. 2016;213:2621\u201333.","journal-title":"J Exp Med"},{"key":"1992_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","volume":"562","author":"D Latorre","year":"2018","unstructured":"Latorre D, Kallweit U, Armentani E, et al. T\u00a0cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562:63\u20138.","journal-title":"Nature"},{"key":"1992_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jneuroim.2017.05.001","volume":"309","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Burgdorf KS, Holm A, Ullum H, Jennum P, Knudsen S. Absence of autoreactive CD4(+) T-cells targeting HLA-DQA1*01:02\/DQB1*06:02 restricted hypocretin\/orexin epitopes in narcolepsy type\u00a01 when detected by EliSpot. J Neuroimmunol. 2017;309:7\u201311.","journal-title":"J Neuroimmunol"},{"key":"1992_CR39","doi-asserted-by":"publisher","first-page":"E12323","DOI":"10.1073\/pnas.1818150116","volume":"115","author":"G Luo","year":"2018","unstructured":"Luo G, Ambati A, Lin L, et al. Autoimmunity to hypocretin and molecular mimicry to flu in type\u00a01 narcolepsy. Proc Natl Acad Sci U S A. 2018;115:E12323\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1992_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/sleep\/32.8.979","volume":"32","author":"A Aran","year":"2009","unstructured":"Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32:979\u201383.","journal-title":"Sleep"},{"key":"1992_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ana.22587","volume":"70","author":"F Han","year":"2011","unstructured":"Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70:410\u20137.","journal-title":"Ann Neurol"},{"key":"1992_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41439-018-0033-7","volume":"6","author":"T Miyagawa","year":"2019","unstructured":"Miyagawa T, Tokunaga K. Genetics of narcolepsy. Hum Genome Var. 2019;6:4.","journal-title":"Hum Genome Var"},{"key":"1992_CR43","doi-asserted-by":"publisher","first-page":"e1003270","DOI":"10.1371\/journal.pgen.1003270","volume":"9","author":"J Faraco","year":"2013","unstructured":"Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T\u00a0cells in narcolepsy. PLoS Genet. 2013;9:e1003270.","journal-title":"PLoS Genet"},{"key":"1992_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/ejhg.2015.4","volume":"23","author":"A Holm","year":"2015","unstructured":"Holm A, Lin L, Faraco J, et al. EIF3G is associated with narcolepsy across ethnicities. Eur J Hum Genet. 2015;23:1573\u201380.","journal-title":"Eur J Hum Genet"},{"key":"1992_CR45","first-page":"16","volume":"6","author":"AM Morse","year":"2018","unstructured":"Morse AM, Sanjeev K. Narcolepsy and psychiatric disorders: comorbidities or shared pathophysiology? Med Sci (Basel). 2018;6:16.","journal-title":"Med Sci (Basel)"},{"key":"1992_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CL Bassetti","year":"2019","unstructured":"Bassetti CL, Adamantidis A, Burdakov D, et al. Narcolepsy\u2014clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519\u201339.","journal-title":"Nat Rev Neurol"},{"key":"1992_CR47","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"1992_CR48","first-page":"106","volume":"7","author":"AM Morse","year":"2019","unstructured":"Morse AM. Narcolepsy in children and adults: a guide to improved recognition, diagnosis and management. Med Sci (Basel). 2019;7:106.","journal-title":"Med Sci (Basel)"},{"key":"1992_CR49","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.5665\/sleep.5842","volume":"39","author":"M Filardi","year":"2016","unstructured":"Filardi M, Pizza F, Bruni O, Natale V, Plazzi G. Circadian rest-activity rhythm in pediatric type\u00a01 narcolepsy. Sleep. 2016;39:1241\u20137.","journal-title":"Sleep"},{"key":"1992_CR50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.sleep.2014.08.017","volume":"16","author":"M Filardi","year":"2015","unstructured":"Filardi M, Pizza F, Martoni M, Vandi S, Plazzi G, Natale V. Actigraphic assessment of sleep\/wake behavior in central disorders of hypersomnolence. Sleep Med. 2015;16:126\u201330.","journal-title":"Sleep Med"},{"key":"1992_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2021.06.033","volume":"85","author":"EW Torstensen","year":"2021","unstructured":"Torstensen EW, Pickering L, Kornum BR, Wanscher B, Baandrup L, Jennum PJ. Diagnostic value of actigraphy in hypersomnolence disorders. Sleep Med. 2021;85:1\u20137.","journal-title":"Sleep Med"},{"key":"1992_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sleep.2016.12.020","volume":"32","author":"K Benmedjahed","year":"2017","unstructured":"Benmedjahed K, Wang YG, Lambert J, et al. Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported measures. Sleep Med. 2017;32:143\u20139.","journal-title":"Sleep Med"},{"key":"1992_CR53","doi-asserted-by":"publisher","first-page":"737","DOI":"10.5664\/jcsm.6596","volume":"13","author":"U Kallweit","year":"2017","unstructured":"Kallweit U, Schmidt M, Bassetti CL. Patient-reported measures of narcolepsy: the need for better assessment. J Clin Sleep Med. 2017;13:737\u201344.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/NSS.S140143","volume":"9","author":"YG Wang","year":"2017","unstructured":"Wang YG, Benmedjahed K, Lambert J, et al. Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. Nat Sci Sleep. 2017;9:201\u201311.","journal-title":"Nat Sci Sleep"},{"key":"1992_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","volume":"30","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369\u201379.","journal-title":"CNS Drugs"},{"key":"1992_CR56","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.smrv.2021.101510","volume":"59","author":"M Filardi","year":"2021","unstructured":"Filardi M, D\u2019Anselmo A, Agnoli S, et al. Cognitive dysfunction in central disorders of hypersomnolence: a systematic review. Sleep Med Rev. 2021;59:101510.","journal-title":"Sleep Med Rev"},{"key":"1992_CR57","doi-asserted-by":"publisher","first-page":"e0182085","DOI":"10.1371\/journal.pone.0182085","volume":"12","author":"M Filardi","year":"2017","unstructured":"Filardi M, Pizza F, Tonetti L, Antelmi E, Natale V, Plazzi G. Attention impairments and ADHD symptoms in adult narcoleptic patients with and without hypocretin deficiency. PLoS ONE. 2017;12:e0182085.","journal-title":"PLoS ONE"},{"key":"1992_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2869.2004.00427.x","volume":"13","author":"C Schneider","year":"2004","unstructured":"Schneider C, Fulda S, Schulz H. Daytime variation in performance and tiredness\/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls. J Sleep Res. 2004;13:373\u201383.","journal-title":"J Sleep Res"},{"key":"1992_CR59","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.5664\/jcsm.4042","volume":"10","author":"J Thomann","year":"2014","unstructured":"Thomann J, Baumann CR, Landolt HP, Werth E. Psychomotor vigilance task demonstrates impaired vigilance in disorders with excessive daytime sleepiness. J Clin Sleep Med. 2014;10:1019\u201324.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR60","doi-asserted-by":"publisher","first-page":"e12689","DOI":"10.1111\/jsr.12689","volume":"28","author":"C Maness","year":"2019","unstructured":"Maness C, Saini P, Bliwise DL, Olvera V, Rye D, Trotti LM. Systemic exertion intolerance disease\/chronic fatigue syndrome is common in sleep center patients with hypersomnolence: a retrospective pilot study. J Sleep Res. 2019;28:e12689.","journal-title":"J Sleep Res"},{"key":"1992_CR61","doi-asserted-by":"publisher","unstructured":"Bassetti CL, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res. 2021;e13387. https:\/\/doi.org\/10.1111\/jsr.13387.","DOI":"10.1111\/jsr.13387"},{"key":"1992_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.sleep.2019.08.008","volume":"66","author":"G Carls","year":"2020","unstructured":"Carls G, Reddy SR, Broder MS, et al. Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities. Sleep Med. 2020;66:110\u20138.","journal-title":"Sleep Med"},{"key":"1992_CR63","unstructured":"Nallu S. Narcolepsy differential diagnoses. In: Benbadis SR, editor. Medscape: Drugs & Diseases. WebMD. https:\/\/emedicine.medscape.com\/article\/1188433-differential. Updated August 3, 2020. Accessed 28 July 2021."},{"key":"1992_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5664\/jcsm.1780","volume":"8","author":"MR Ebben","year":"2012","unstructured":"Ebben MR, Krieger AC. Narcolepsy with cataplexy masked by the use of nicotine. J Clin Sleep Med. 2012;8:195\u20136.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR65","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0004867419887795","volume":"54","author":"D Wei\u00df","year":"2020","unstructured":"Wei\u00df D, Kluge M. Waiting 40 years for the correct diagnosis: a complex case of comorbid narcolepsy and ADHD. Aust N Z J Psychiatry. 2020;54:439\u201340.","journal-title":"Aust N Z J Psychiatry"},{"key":"1992_CR66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","volume":"43","author":"A Cohen","year":"2018","unstructured":"Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14\u20138.","journal-title":"Sleep Med"},{"key":"1992_CR67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11065-020-09443-7","volume":"31","author":"X Li","year":"2021","unstructured":"Li X, Sanford LD, Zong Q, et al. Prevalence of depression or depressive symptoms in patients with narcolepsy: a systematic review and meta-analysis. Neuropsychol Rev. 2021;31:89\u2013102.","journal-title":"Neuropsychol Rev"},{"key":"1992_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/jsr.12007","volume":"22","author":"A Silvani","year":"2013","unstructured":"Silvani A, Grimaldi D, Barletta G, et al. Cardiovascular variability as a function of sleep\u2013wake behaviour in narcolepsy with cataplexy. J Sleep Res. 2013;22:178\u201384.","journal-title":"J Sleep Res"},{"key":"1992_CR69","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fendo.2019.00830","volume":"10","author":"E Milbank","year":"2019","unstructured":"Milbank E, L\u00f3pez M. Orexins\/hypocretins: key regulators of energy homeostasis. Front Endocrinol (Lausanne). 2019;10:830.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1992_CR70","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.sleep.2021.02.040","volume":"81","author":"S Mohammadi","year":"2021","unstructured":"Mohammadi S, Moosaie F, Saghazadeh A, Mahmoudi M, Rezaei N. Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis. Sleep Med. 2021;81:268\u201384.","journal-title":"Sleep Med"},{"key":"1992_CR71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fendo.2020.00145","volume":"11","author":"ME Straat","year":"2020","unstructured":"Straat ME, Schinkelshoek MS, Fronczek R, Lammers GJ, Rensen PC, Boon MR. Role of brown adipose tissue in adiposity associated with narcolepsy type\u00a01. Front Endocrinol (Lausanne). 2020;11:145.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1992_CR72","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705\u201311.","journal-title":"Sleep"},{"key":"1992_CR73","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3949\/ccjm.85a.17086","volume":"85","author":"EC Golden","year":"2018","unstructured":"Golden EC, Lipford MC. Narcolepsy: diagnosis and management. Cleve Clin J Med. 2018;85:959\u201369.","journal-title":"Cleve Clin J Med"},{"key":"1992_CR74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s11325-019-01894-4","volume":"24","author":"C Franceschini","year":"2020","unstructured":"Franceschini C, Pizza F, Antelmi E, Folli MC, Plazzi G. Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. Sleep Breath. 2020;24:615\u201327.","journal-title":"Sleep Breath"},{"key":"1992_CR75","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.slsci.2014.07.023","volume":"7","author":"HA Agudelo","year":"2014","unstructured":"Agudelo HA, Correa UJ, Sierra JC, Pandi-Perumal SR, Schenck CH. Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy? Sleep Sci. 2014;7:30\u201342.","journal-title":"Sleep Sci"},{"key":"1992_CR76","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/NSS.S162762","volume":"12","author":"EC Barker","year":"2020","unstructured":"Barker EC, Flygare J, Paruthi S, Sharkey KM. Living with narcolepsy: current management strategies, future prospects, and overlooked real-life concerns. Nat Sci Sleep. 2020;12:453\u201366.","journal-title":"Nat Sci Sleep"},{"key":"1992_CR77","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5664\/jcsm.9328","volume":"15","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;15:10. https:\/\/doi.org\/10.5664\/jcsm.9328.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR78","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1468-1331.2006.01473.x","volume":"13","author":"M Billiard","year":"2006","unstructured":"Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13:1035\u201348.","journal-title":"Eur J Neurol"},{"key":"1992_CR79","unstructured":"XYREM\u00ae (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2020."},{"key":"1992_CR80","unstructured":"XYWAV\u2122 (calcium, magnesium, potassium, and sodium oxybates) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2021."},{"key":"1992_CR81","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5664\/jcsm.2048","volume":"8","author":"MK Alshaikh","year":"2012","unstructured":"Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8:451\u20138.","journal-title":"J Clin Sleep Med"},{"key":"1992_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-319-23739-8_7","volume-title":"Narcolepsy: a clinical guide","author":"N Cornay-Manalo","year":"2016","unstructured":"Cornay-Manalo N, Attarian H. Narcolepsy in the older adult. In: Goswami M, Thorpy MJ, Pandi-Perumal SR, editors. Narcolepsy: a clinical guide. 2nd ed. Cham: Springer; 2016. p. 69\u201380.","edition":"2"},{"key":"1992_CR83","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa206","author":"RK Bogan","year":"2020","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2020. https:\/\/doi.org\/10.1093\/sleep\/zsaa206.","journal-title":"Sleep"},{"key":"1992_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34:9\u201327.","journal-title":"CNS Drugs"},{"key":"1992_CR85","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.2147\/DDDT.S101145","volume":"12","author":"A Romigi","year":"2018","unstructured":"Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:2665\u201375.","journal-title":"Drug Des Devel Ther"},{"key":"1992_CR86","unstructured":"WAKIX\u00ae (pitolisant) [prescribing information]. Plymouth Meeting, PA: Harmony Biosciences, LLC; 2021."},{"key":"1992_CR87","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/14656566.2019.1617273","volume":"20","author":"VC Abad","year":"2019","unstructured":"Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019;20:1189\u201399.","journal-title":"Expert Opin Pharmacother"},{"key":"1992_CR88","unstructured":"SUNOSI\u2122 (solriamfetol) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2019."},{"key":"1992_CR89","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.sleep.2015.05.013","volume":"16","author":"RK Bogan","year":"2015","unstructured":"Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16:1102\u20138.","journal-title":"Sleep Med"},{"key":"1992_CR90","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","volume":"199","author":"PK Schweitzer","year":"2019","unstructured":"Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial. Am J Respir Crit Care Med. 2019;199:1421\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"1992_CR91","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85:359\u201370.","journal-title":"Ann Neurol"},{"key":"1992_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsy185","volume":"41","author":"P Lehert","year":"2018","unstructured":"Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41:1\u201313. https:\/\/doi.org\/10.1093\/sleep\/zsy185.","journal-title":"Sleep"},{"key":"1992_CR93","unstructured":"PROVIGIL\u00ae (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015."},{"key":"1992_CR94","unstructured":"Greenblatt K, Adams N. Modafinil. NCBI Bookshelf. Treasure Island: StatPearls Publishing; January 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531476\/. Updated September 11, 2020. Accessed 29 July 2021."},{"key":"1992_CR95","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40264-013-0025-y","volume":"36","author":"M Davies","year":"2013","unstructured":"Davies M, Wilton L, Shakir S. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England. Drug Saf. 2013;36:237\u201346.","journal-title":"Drug Saf"},{"key":"1992_CR96","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00213-017-4650-5","volume":"235","author":"PC Dolder","year":"2018","unstructured":"Dolder PC, M\u00fcller F, Schmid Y, Borgwardt SJ, Liechti ME. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology. 2018;235:467\u201379.","journal-title":"Psychopharmacology"},{"key":"1992_CR97","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers Y, Siegel JM, Lopez R, Torontali ZA, Peever JH. Cataplexy\u2014clinical aspects, pathophysiology and management strategy. Nat Rev Neurol. 2014;10:386.","journal-title":"Nat Rev Neurol"},{"key":"1992_CR98","unstructured":"NCT02720744. Once-nightly sodium oxybate for treatment of excessive daytime sleepiness and cataplexy in narcolepsy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720744. Updated April 3, 2020. Accessed 29 July 2021."},{"key":"1992_CR99","unstructured":"Avadel Pharmaceuticals. Avadel Pharmaceuticals announces FDA acceptance of new drug application for FT218 in adults with narcolepsy for the treatment of excessive daytime sleepiness and cataplexy. Intrado GlobalNewswire website. https:\/\/www.globenewswire.com\/news-release\/2021\/03\/01\/2184208\/0\/en\/Avadel-Pharmaceuticals-Announces-FDA-Acceptance-of-New-Drug-Application-for-FT218-in-Adults-with-Narcolepsy-for-the-Treatment-of-Excessive-Daytime-Sleepiness-and-Cataplexy.html. Published March 1, 2021. Accessed 12 Aug 2021."},{"key":"1992_CR100","unstructured":"Takeda Pharmaceuticals Protocol. A phase\u00a01b, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 in sleep-deprived healthy adults utilizing modafinil as an active comparator. https:\/\/clinicaltrials.gov\/ProvidedDocs\/06\/NCT03522506\/Prot_000.pdf. Protocol approved May 8, 2018. Accessed 29 July 2021."},{"key":"1992_CR101","unstructured":"NCT03332784. Phase\u00a01 TAK-925 study in healthy adult and elderly volunteers and participants with narcolepsy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03332784. Updated March 30, 2021. Accessed 12 Aug 2021."},{"key":"1992_CR102","unstructured":"NCT04096560. A study of TAK-994 in adults with type\u00a01 and type\u00a02 narcolepsy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04096560. Updated August 4, 2021. Accessed 12 Aug 2021."},{"key":"1992_CR103","unstructured":"Takeda. US Food and Drug Administration grants breakthrough therapy designation to Takeda\u2019s investigational compound, TAK-994, an oral orexin agonist in clinical development for narcolepsy type\u00a01 (NT1). https:\/\/www.takeda.com\/newsroom\/newsreleases\/2021\/us-food-and-drug-administration-grants-breakthrough-therapy-designation-to-takedas-investigational-compound-tak-994\/. Published July 28, 2021. Accessed 12 Aug 2021."},{"key":"1992_CR104","unstructured":"Adis Insight. Reboxetine\u2013Axsome Therapeutics. https:\/\/adisinsight.springer.com\/drugs\/800053169. Updated March 26, 2021. Accessed 12 Aug 2021."},{"key":"1992_CR105","unstructured":"Axsome Therapeutics. Axsome Therapeutics announces expedited development of AXS-12 for the treatment of narcolepsy based on FDA breakthrough therapy meeting. Intrado GlobalNewswire website. https:\/\/www.globenewswire.com\/en\/news-release\/2020\/09\/21\/2096384\/33090\/en\/Axsome-Therapeutics-Announces-Expedited-Development-of-AXS-12-for-the-Treatment-of-Narcolepsy-Based-on-FDA-Breakthrough-Therapy-Meeting.html. Published September 21, 2020. Accessed 12 Aug 2021."},{"key":"1992_CR106","unstructured":"NCT04072380. A study to evaluate safety, and efficacy of SUVN-G3031 in patients with narcolepsy with and without cataplexy (SUVN-G3031). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04072380. Updated April 12, 2021. Accessed 29 July 2021."},{"key":"1992_CR107","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S1474-4422(16)30204-6","volume":"15","author":"K Maski","year":"2016","unstructured":"Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. Lancet Neurol. 2016;15:1170\u201381.","journal-title":"Lancet Neurol"},{"key":"1992_CR108","unstructured":"Ruscin JM, Linnebur SA. Pharmacokinetics in older adults. Merck Manual Professional Version. https:\/\/www.merckmanuals.com\/professional\/geriatrics\/drug-therapy-in-older-adults\/pharmacokinetics-in-older-adults. Updated July 2021. Accessed 20 Aug 2021."},{"key":"1992_CR109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/NSS.S245020","volume":"13","author":"VC Abad","year":"2021","unstructured":"Abad VC. Profile of solriamfetol in the management of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea: focus on patient selection and perspectives. Nat Sci Sleep. 2021;13:75\u201391.","journal-title":"Nat Sci Sleep"},{"key":"1992_CR110","unstructured":"Narcolepsy fact sheet. National Institute of Neurological Disorders and Stroke website. https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Narcolepsy-Fact-Sheet. Updated September 30, 2020. Accessed 20 Aug 2021."},{"key":"1992_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00139","author":"J Wisor","year":"2013","unstructured":"Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013. https:\/\/doi.org\/10.3389\/fneur.2013.00139.","journal-title":"Front Neurol"},{"key":"1992_CR112","unstructured":"NUVIGIL\u00ae (armodafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.;2018."},{"key":"1992_CR113","unstructured":"RITALIN\u00ae (methylphenidate hydrochloride) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019."},{"key":"1992_CR114","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/14656566.2017.1323877","volume":"18","author":"U Kallweit","year":"2017","unstructured":"Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18:809\u201317.","journal-title":"Expert Opin Pharmacother"},{"key":"1992_CR115","unstructured":"EFFEXOR XR\u00ae (venlafaxine Extended-Release) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; 2021."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01992-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T02:19:42Z","timestamp":1676081982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01992-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01992-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,11]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}